Limited cash pile focuses the mind for Lipocine

26 September 2022

US biopharma Lipocine (Nasdaq: LPCN) has come up with a plan as the end of its cash pile starts to appear on the horizon.

The Salt Lake City-based company, which is seeking to leverage its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules, has announced its plans to focus on treating CNS disorders.

"We believe that this strategy will allow us to diversify risk and can create opportunities for non-dilutive financing"Lipocine had $37.4 million in cash and other assets as of June 30 this year. The firm believes that this will be sufficient to support operations and capital expenditure until at least September 30, 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK